Highlight

1. ClearMOA

1. Nonalcoholic steatohepatitis (NASH) is now the common form of chronic liver disease globally.

2. Despite its significant health care burden, there are no FDA-approved medications for NASH. Vitamin E and pioglitazone are not applicable to all patients. Obeticholic acid may raise concerns about long-term cardiovascular morbidity.

3. Inhibition of ACC enzymes pharmacologically provides an attractive approach to treating NAFLD/NASH by decreasing hepatic lipid synthesis while simultaneously increasing fatty acid oxidation.

2. Excellent effect in multiple NASH models.

1) In HFD induced fatty liver model, asset can significantly reduce serum ALT content, liver TG content and NAS score. The therapeutic effect of each dose group is equivalent to that of GS0976.

2) In AMLN induced short-term NASH model, All doses of this asset can improve liver function and reduce dyslipidemia, liver lipid accumulation and NAS score. And asset has the same effect as GS0976 (3mpk) in improving liver fibrosis.

3) In AMLN induced long-term NASH with liver fibrosis model, asset (5mpk) can improve liver function and reduce dyslipidemia, liver CHO content, liver lipid accumulation and NAS score.

3. PK&PD: fast oral absorption , high bioavailability, high concentration of liver (target tissue) distribution, and the metabolites in the body are mainly prototype drugs, which are excreted with feces, without obvious drug interaction.

4. Excellent safety for treating NASH.

hERG IC50＞100 μM; no genotoxicity; no cardiovascular, respiratory and central nervous system toxicity

Research progress：

1. InAMLN induced long-term NASH with liver fibrosis model, 5 mpk asset can reduce the fibrosis more than 10 mpk GS0976.

2. Asset has approved IND.